Independent technical profiles for the seven most-studied research peptides. Each profile covers mechanism, published dosing ranges, side-effect patterns from case literature, and current pre-clinical or clinical status.
Pentadecapeptide from human gastric juice. Drives angiogenesis, tendon/ligament repair, and the gut-brain axis. The most-discussed healing peptide in biohacker culture and the most-replicated in pre-clinical animal data.
Synthetic version of the active region of Thymosin Beta-4. Actin-sequestering peptide driving cell migration, cardiac repair, and wound-healing acceleration. The peptide that built the modern systemic-recovery category.
Copper-binding tripeptide that resets ~4,000 genes toward youthful expression patterns. The most-cited peptide in cosmeceutical research, with strong dermal regeneration and antioxidant evidence.
Khavinson's tetrapeptide (Ala-Glu-Asp-Gly) — telomerase activator with decade-spanning Russian longevity trials. The most extensive human-trial dataset of any peptide in the longevity space.
The cleanest of the GHS class — selectively activates GHS-R1a without the cortisol/prolactin spillover of older GHRPs. The workhorse of modern GH-axis stacking protocols.
Albumin-binding GHRH analog. The DAC variant extended half-life from minutes to days, making once-weekly sustained GH-axis stimulation feasible for the first time.
The first 29 residues of endogenous GHRH. FDA-approved for pediatric GH deficiency in 1997; remains the benchmark against which every subsequent GHRH analog is compared.
We profile peptides with at least three independent peer-reviewed publications and a documented mechanism. Compounds in earlier pre-clinical phases are tracked on the pipeline page rather than profiled here. Cosmetic-only compounds (Argireline, Matrixyl, etc.) are out of scope.